Immunohistochemistry studies in our laboratory have confirmed that versican is increased in the stromal compartment of serous ovarian carcinoma compared to the stroma of normal ovaries or benign ovarian tumors (Figure 1). Here, VCAN is linked to ovarian serous carcinoma.